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A B S T R A C T
Several clinical and epidemiological studies have suggested a significant role of es-
sential micronutrients in patients with heart failure, although in clinical practice the 
use of these agents is controversial. An overview is herein attempted of recent data 
regarding current knowledge on the benefits of vitamin D and B1 supplementation 
and iron therapy in patients with chronic heart failure.
I N T R O D U C T I O N
Congestive heart failure (HF) is a chronic medical condition with 1-3% prevalence 
in Western countries.1 In spite of innovations in medical therapy, the incidence of this 
condition is rising, while its morbidity and mortality rates continue to remain high. 
Several clinical and epidemiological studies have suggested a significant role of es-
sential micronutrients in HF patients, although in routine clinical practice the use of 
these agents has remained controversial for some time. However, recent trials provide 
evidence for certain benefits from vitamins D, B1 and iron in patients with chronic HF.
V I T A M I N  D
The metabolism of Vitamin D is complex and involves many organ systems. This 
is illustrated in Figure 1.
V I T A M I N  D  S O U R C e S  A N D  A C T I O N
In skin exposed to ultraviolet B light, the provitamin 7-dehydrocholesterol is 
converted to vitamin D3 (cholecarciferol). Vitamin D3 is also obtained from dietary 
sources. Vitamin D3 is then metabolized in the liver to 25-OH Vitamin D. Then it is 
often used to determine a patient’s vitamin D status. 25-OH vitamin D is converted 
in the kidneys to its active form 1,25-OH vitamin D, and this conversion is regulated 
by parathyroid hormone levels, serum calcium and phosphorus levels.2 People obtain 
vitamin D from sunlight exposure, dietary sources and oral supplements. Only a few 
foods such as salmon, eel and herring are good source of vitamin D. Luckily ultraviolet 
B-induced synthesis of vitamin D is extremely effective.
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More than 200 genes, which regulate cellular proliferation, 
differentiation, apoptosis and angiogenesis are either directly 
or indirectly controlled by 1,25-OH vitamin D.3 Vitamin D is 
also associated with increased insulin production,4 decreases 
renin synthesis and increases myocardial contraction.
The active form of vitamin D is transported protein-bound 
in the blood and it is delivered in free form to cells of various 
target organs. Specific nuclear receptor proteins are found in 
many of these organs including brain, skin, skeletal muscles, 
cardiomyocytes,2 vascular smooth muscles,5 endothelium,6 
circulating monocytes and activated B and T lymphocytes.
In vitro studies demonstrate that vitamin D suppresses 
proinflammatory cytokines, e.g. interleukin (IL)-6, IL-2, 
interferon-gamma, tumor necrosis factor (TNF)-alpha) and 
upregulates levels of the anti-inflammatory cytokine, e.g. IL-10.7 
e p I D e M I O l O g y  O f  V I T A M I N  D  D e f I C I e N C y
The different stages of vitamin D status can be classified 
as deficiency, insufficiency, hypovitaminosis, adequacy and 
toxicity. Vitamin D deficiency is associated with severe clinical 
symptoms such as rickets, osteomalacia, myopathy and cal-
cium malabsorption. In vitamin D insufficiency, biochemical 
alterations, such as low intestinal calcium absorption and 
mild hyperparathyroidism, are noted without severe clinical 
symptoms. In addition, calcitriol levels remain normal at the 
expense of elevated parathyroid hormone levels.8 In hypovi-
fIgURe 1. Vitamin D metabolism.
taminosis D, the body stores of vitamin D are already low but 
only minor physiological abnormalities, such as an elevated 
parathyroid hormone level are seen.9 In vitamin D adequacy 
there are no perturbations in dependent bodily functions. In 
vitamin D toxicity there is intestinal calcium hyper-absorption 
and increased bone resorption which lead to hypercalcemia.
According with the National Health and Nutrition Exami-
nation Survey (NHANES III), low 25-OH vitamin D levels 
were associated with multiple health problems including 
coronary vascular disease, cancer, congestive heart failure, 
hypertension and diabetes.10 There are data which suggest an 
association between low levels of 25-hydroxyvitamin-D and the 
accelerated development of cardiovascular disease11-13 and its 
prevalence was noted to increase with increasing distance from 
the Ecuador because of sunlight deficiency. Recent studies also 
suggest that low vitamin D levels (<30 mg/ml [75 mmol/l]) are 
linked with the occurrence of fatal stroke,14 sudden cardiac 
death,15 valvular aortic stenosis and heart failure. Importantly, 
41% of men and 53% of women4 in the United States have 
levels of 25-OH Vitamin D below 28 ng/ml. In the elderly 
population in the United States and Europe, 40% to 100% 
are vitamin D deficient. It has been estimated that one billion 
people worldwide have vitamin D deficiency or insufficiency.16 
V I T A M I N  D  D e f I C I e N C y  
A N D  C h R O N I C  h e A R T  fA I l U R e
Congestive HF is the end stage of hypertensive, coronary or 
valvular disease in many patients. There is increasing evidence 
to support the motion that low vitamin D status may be an im-
portant factor in the development and the pathogenesis of HF.
Recently, in the pathophysiology of HF, ideas have ex-
panded to a more complex concept for vitamin D,17 which 
seems to have indirect effect on risk factors of disease and 
direct effect on myocytes. Four major potential mechanisms 
may be important to explain the direct effects of vitamin D 
against the development of congestive HF.19 These include 
the effect on myocardial contractile function, the regulation of 
inflammation cytokines, the influence on extracellular matrix 
remodeling and the regulation of natriuretic hormone secre-
tion. In addition, vitamin D has a number of actions (Figure 
2) that should help prevent hypertension,20 a significant risk 
factor for HF.
Vitamin D suppresses the renin-angiotensin-aldosterone 
system and thus protects the kidneys. More than 20 years ago, 
several studies showed the relationship between vitamin D 
and cardiovascular homeostasis. Excess parathormone levels 
are associated with low levels of vitamin D, which may play 
a role in cardiovascular disease by leading to cardiomyocyte 
hypertrophy and interstitial fibrosis of the heart. Vitamin D 
suppresses cardiac hypertrophy, as it was found in animal 
studies and also plays a role in cardiomyocyte relaxation in-
validating the hypercontractility associated with diastolic HF.
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fIgURe 2. Cardiovascular consequences of vitamin D defi-
ciency.
V I T A M I N  D  A N D  h e A R T  T R A N S p l A N T A T I O N
In patients who are at end-stage HF, the question arises 
whether these individuals would be at high risk of vitamin D 
deficiency. Stein et al measured serum 25-hydroxy-vitamin D3 
immediately after transplantation in heart transplant recipi-
ents. Levels were low.21 This could be explained by malabsorp-
tion and limited exposure to sunlight. However, in order to 
estimate the role of low levels of vitamin D during the pre- and 
post- transplant period in improving survival or preventing 
graft rejection for recipients, further investigation is needed.
V I T A M I N  D  S U p p l e M e N T A T I O N  A N D  S U R V I VA l 
I N  h e A R T  fA I l U R e
Vitamin D requirements vary between 60 to 200 IU per 
day, depending in part on age and sun exposure. Other investi-
gators believe that optimal amounts are closer to 1000 IU daily.
Apart from an increased propensity to vitamin D deficiency 
in chronic HF patients, no clear data exist on improvement in 
clinical outcomes. Pitas et al performed a systematic review of 
13 observational studies and 18 trials evaluating the effect of vi-
tamin D supplementation on cardiometabolic outcomes.22 The 
analysis revealed mixed results and the authors concluded that 
the association between vitamin D status and cardiometabolic 
outcomes was uncertain, and no significant benefit in clinical 
practice of supplementation was evident.
In a 20-week trial of vitamin D supplementation in patients 
older >70 years of age with HF and vitamin D insufficiency, a 
regimen of 100.000 IU of vitamin D or placebo at baseline at 
0 and 10 weeks did not improve functional exercise tolerance 
in the 6-minute walk test. A decrease in B-type natriuretic 
peptide, a secondary outcome, was an intriguing observation 
in the treatment group, but it was counter-balanced by a de-
crease of quality of life. This high-quality trial contributes to 
the evaluation of the role of vitamin D in chronic HF. However, 
prospective studies are required which should focus on higher 
doses of vitamin D.
I R O N
The importance of iron to human health is well-known and 
there is increasing interest in identifying the role of iron in 
cardiac failure. In chronic HF, treatment of anemia in patients 
with reduced left ventricular ejection fraction was tradition-
ally based on erythropoietin-stimulating agents. Debate has 
been going on regarding whether erythropoietin is needed in 
addition to iron to improve exercise capacity and symptoms 
in anemic HF patients. 
Recent studies have shown that treatment with intrave-
nous (IV) iron can improve the quality of life in patients with 
chronic HF and iron deficiency, with or without anemia. In 
chronic HF the impairment of cardiac function affects the 
functional capacity of other organs such as the kidneys and 
skeletal muscles. The most prevalent comorbidities in chronic 
HF are chronic kidney disease and anemia.23 The diagnosis and 
treatment of these comorbidities by physicians will most likely 
increase mechanisms to correct the inadequate tissue oxygen 
supply and impaired oxygen used by the skeletal muscles for 
improving exercise tolerance.24 
Anemia in chronic HF can be the consequence of reduced 
glomerular filtration rate, impaired erythropoietin production 
and hemodilution.25 In one study of 148 patients with anemia 
and HF, the majority of patients – about 57% - were found 
with anemia of chronic disease, due to inadequate production 
of erythropoietin relative to the degree of anemia and/or a 
defective iron supply for erythropoiesis. These findings seem to 
be correlated with elevated level of inflammatory cytokines.26 
C O R R e C T I O N  O f  A N e M I A
In some small initial studies of correction of anemia in 
individuals with chronic HF and chronic kidney disease, 
Silverberg et al27 achieved an increase in hemoglobin, left 
ventricular ejection fraction, functional class and decreases 
in hospitalizations for HF with erythropoietin and IV iron. In 
another study of anemic patients (hemoglobin ≤12 g/dl) with 
stable chronic HF, IV injection of iron sucrose alone over 12 
days increased hemoglobin levels, decreased symptoms and 
improved exercise capacity.28 However, the medical community 
ascribed a secondary role to the administration of oral or in-
travenous iron, and erythropoietin-stimulating agents received 
most of the attention from researchers because of its benefits.
Two recent meta-analyses of these studies with erythropoi-
etin-stimulating agents demonstrated a beneficial effect on HF 
hospitalizations and some signs of symptomatic improvement 
but no decrease or increase in mortality. In larger studies, how-
ever, there was no significant improvement in exercise capacity 
despite the increase in hemoglobin.29,30 In addition, if we take 
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into account the large number of patients participating in the 
TREAT trial (~4000), in those with HF, anemia and chronic 
kidney disease who received erythropoietin-stimulating 
agents, there was a neutral effect on mortality and non-fatal 
HF events. Furthermore, a higher risk of venous and arterial 
thromboembolic events, as well as stroke, and a trend toward 
hypertension were noted with the use of the erythropoietin-
stimulating agent. 
These findings are in contrast to the consequent clinical 
improvements found in recent studies in patients with HF and 
iron deficiency with or without anemia who received only IV 
iron. In the FAIR-HF trial, 459 patients were randomised to 
receive IV iron as ferric carboxymaltose vs placebo.38 Among 
patients who received IV iron, 50% reported being much 
or moderately improved, as compared with 28% of patients 
receiving placebo, according to the patient global assessment 
(odds ration for improvement 2,51: 95% confidence intervals-
CI, 1.75-3.61). There was also a significant improvement in the 
NYHA functional class. In the distance on the 6-minute walk 
test and quality-of-life assessments, there were no differences, 
and there was a trend for fewer hospitalizations and for any 
cardiovascular disease in the IV iron group. It is important to 
mention that treatment with IV iron was beneficial to both 
patients, with and without anemia.
In the FERRIC-HF trial the findings were also similar 
and consistent with the concept that impaired physical per-
formance in iron-deficiency animal models is due to two facts: 
1) The impaired oxidative capacity of the skeletal muscle, as 
myoglobin, mitochondrial cytochrome and total mitochondrial 
oxidative capacity decreases, 2) The diminished oxygen trans-
port when anemia develops.18 Finally, in the FAIR-HF trial, 
the outcomes assessed and the findings tended to estimate 
lower intensity endurance exercise correlating tightly with 
tissue iron deficiency. 
C h R O N I C  h e A R T  fA I l U R e  A N D  I R O N 
D e f I C I e N C y
In order to evaluate the anemia and to look further into 
its pathogenesis in patients with chronic HF, we must also 
assess vitamin B12 and folic acid levels. According with some 
studies, estimates of deficiency in these vitamins in individuals 
with chronic HF and anemia reach up to 19%. However, this 
seems to be of secondary importance, while iron deficiency 
plays a critical role in the anemia of HF and it can contribute to 
erythropoietin resistance, as the bone marrow will not respond 
to erythropoietin unless adequate iron stores are present.
An important point, according to a study by Nanas et al,31 
is that despite apparently adequate iron stores as assessed by 
serum iron and ferritin, up to 73% of patients with anemia, 
normal kidney function and advanced HF had iron deficiency 
as estimated by bone marrow aspiration. This study demon-
strated that neither serum iron nor ferritin levels proved to be 
reliable markers of iron deficiency. The reason for a higher 
than expected serum ferritin may be due to inflammatory 
mediators that accompany the chronic HF syndrome and this 
is why in those patients a higher cut-off value of ferritin (<100 
μg/lt) determines the absolute iron deficiency. 
Iron is an essential trace element that can donate elec-
trons to its ferrous form – Fe(II) – and accept electrons in its 
ferric-form (III). This capability makes it a useful component 
of cytochromes and oxygen-binding molecules, such as hemo-
globin and myoglobin, but can also promote the generation of 
free radicals and makes iron potentially toxic.
D I A g N O S I S  O f  I R O N  D e f I C I e N C y
Diagnosing iron deficiency in patients with HF is very 
important, because iron plays a key role in oxygen uptake, 
transport and storage in the oxidative metabolism of the 
skeletal muscle and in erythropoiesis.32 The evaluation of iron 
metabolism must include the determination of serum iron, 
transferrin, transferrin saturation (TSAT) and ferritin (Figure 
3). Thus, iron deficiency may be identified when ferritin levels 
are <100 μg/l, accompanied by high transferrin and low TSAT; 
functional iron deficiency is defined as ferritin between 100 
and 299 μg/l and TSAT<20% and these patients also benefit 
from IV iron. 
Functional iron deficiency means that there is an increased 
uptake and retention of iron in the cells of the reticuloendothe-
lial system, when we consider anemia of chronic disease, such 
as that of chronic HF. This is achieved by the expression of 
divalent metal transporter 1 (DMI1), which is up-regulated by 
cytokines. DMT1 mediates iron transport into the intestinal 
mucosal cells and into the activated macrophages, but the 
export of iron from these cells is inhibited by down-regulation 
of the expression of ferroportin by means of an increase in 
hepcidin. This protein inhibits iron absorption from the gut 
and hepcidin levels seem to reflect iron load and response to 
erythropoietin rather than inflammation and erythropoietin 
resistance.34 Thus, this condition is associated with normal or 
increased ferritin with low serum iron, low TSAT, low trans-
ferrin and thus poor availability of iron at the bone marrow.33 
In a recent study of 546 patients with systolic chronic HF, 
iron deficiency (absolute or functional) was found in 37% of 
patients, and iron deficiency but not anemia was related to an 
increased risk of death or heart transplantation in multivariable 
analysis reinforcing its position as an independent predictor 
of adverse outcome.
T R e A T M e N T  O f  I R O N  D e f I C I e N C y
In patients with chronic HF and iron deficiency, IV iron 
therapy as demonstrated in FAIR-HF trial improves functional 
class and hemoglobin levels. 35 One could wonder whether 
oral iron, a less expensive therapy, could have a very similar 
therapeutic effect. The answer seems to be negative, because 
the absorption of oral iron preparations in the anemia of 
chronic disease is blocked by hepcidin.36 Furthermore, oral 
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iron administration may be poorly tolerated because of gas-
trointestinal side-effects and a number of drug interactions 
may occur, such as when co-administered with proton pump 
inhibitors, for example. Hepcidin also impairs iron delivery 
to bone marrow, which is why the anemia of chronic disease 
does not respond to oral iron. 
C O N C l U S I O N
Iron is a micronutrient that stands at the core of cellular 
metabolism and is critical for the maintenance of homeosta-
sis. Iron deficiency constitutes a frequent co-morbidity in HF 
patients. Iron deficiency is gaining interest, not only as an 
etiological factor leading to and/or aggravating anemia in HF, 
but also as a therapeutic target. Only recently did clinical stud-
ies demonstrate that in patients with HF and iron deficiency, 
IV iron repletion was well tolerated and improved functional 
status, quality of life and exercise capacity.
It seems reasonable, therefore, to undertake a work-up 
evaluation and, if absolute or functional iron deficiency is 
found, to start treatment with IV iron, although further mor-
tality and morbidity studies would help to further define the 
role of IV iron in HF. 
Intravenous iron is provided as carbohydrate complexes 
with iron in its Fe(III) form and after a few hours following 
its administration it is taken up by the reticuloendothelial 
system. The majority of the dose is deposited in a long-term 
storage and a portion of this iron is bound to transferrin for 
transportation to the bone marrow. In contrast to dextran iron, 
currently used IV iron preparations, ferric saccharate, ferric 
gluconate or ferric carboxymaltose are well tolerated and have 
fewer hypersensitivity reactions. The total iron dose is calcu-
lated according to the Ganzoni’s formula and is administered 
as ferric carboxymaltose in weekly doses of 200 mg as an IV 
bolus injection and discontinued when ferritin reaches levels 
>800 μg/l or when ferritin ranges at 500-800 μg/l, TSAT is 
>50% and hemoglobin level is >16 g/dl. Its usefulness and 
safety appear greater than erythropoietin-stimulating agents 
in patients with anemia and chronic HF. On the other hand, 
as in patients with thalassemia, excessive iron deposition in 
the heart can cause cardiomyopathy, heart failure and cardiac 
arrhythmias, 37 hence close monitoring of this therapy is of 
paramount importance. 
T h I A M I N e  ( V I T A M I N  B 1 )
Vitamin B1, also called thiamine, is one of the 8 B-complex 
vitamins. It is named B1 because it was the first B vitamin 
discovered. These essential micronutrients are water-soluble, 
meaning that the body does not store them, and help the body 
to convert carbohydrates into glucose, which is used for energy 
generation.39 They help the body metabolize fats and protein. 
fIgURe 3. Iron metabolism.
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These are needed for healthy skin, hair, eyes, liver, and mainly 
for good brain function, and all nervous system in general.
Like other vitamins of the B complex, thiamine is some-
times called an “anti-stress” vitamin because it may strengthen 
the immune system and improve the body’s ability to withstand 
stressful conditions.40 Thiamine plays a crucial role in certain 
metabolic reactions and is the one that the body needs to 
form adenosine triphosphate (ATP) which every cell uses 
for energy.40
There are two major sources of thiamine, dietary intake 
and bacterial production. The greatest quantities are in several 
food groups, such as wheat, rice, yeast, pork, beef, poultry, fish, 
milk, green leafy vegetables, nuts and seeds. Conversely, bac-
terial production is extremely small. The quantity of reserves 
of the water-soluble thiamine in the lipid structures of the 
body cell are quite low, with the maximum storage capacity 
of 30 ng. The stored thiamine in the body is depleted within 
two weeks and clinical signs and symptoms appear in almost 
three months of a thiamine-deficient diet. Excess thiamine 
is excreted in the urine, whereas in thiamine deficiency, it is 
generally absent from the urine. However, a patient can be 
clinically thiamine-deficient despite a “normal” serum and 
urinary thiamine excretion level. Consequently, a fixed supply 
of vitamin B1 intake is required regardless of whether urinary 
thiamine excretion is high.
Thiamine is absorbed in the jejunum and ileum by pas-
sive as well active uptake. Then it travels to the liver and by 
facilitated transport enters into the red blood cells. Thiamine 
in serum, which is not protein-bound, is filtered at the glomeru-
lus. Thiamine excretion takes place in the distal nephron. The 
factors that increase the urine flow rate would also increase 
thiamine excretion and may predispose individuals to thiamine 
deficiency.
It is a rare situation for individuals to be deficient in 
thiamine, although alcoholics, patients with Crohn’s disease, 
anorexia, or patients on chronic renal dialysis may be thiamine-
deficient. Depression, irritability and fatigue with abdominal 
discomfort are some symptoms of thiamine deficiency.41 
Individuals with thiamine deficiency may have trouble digest-
ing carbohydrates; this allows pyruvic acid to concentrate in 
the bloodstream, causing shortness of breath, loss of mental 
alertness and cardiac dysfunction (high-cardiac output heart 
failure), a disease known as Beriberi.
Beriberi is the condition in which thiamine has one of the 
most important uses for its therapy. This illness is more com-
mon in underdeveloped countries because of malnutrition. 
Symptoms include shortness of breath because of pulmonary 
congestion, peripheral edema, tingling or burning sensation 
in the hands and feet, and mental confusion.42
The features of thiamine deficiency take one of two forms 
depending on whether the patient has wet or dry Beriberi. 
Patients with wet Beriberi have cardiovascular disturbances, 
which manifest as high-output or low-output cardiac failure, 
systemic vasodilation, lactic acidosis, edema with fluid re-
tention. On the other hand, patients with dry Beriberi have 
neurological symptoms in the central and peripheral nervous 
systems, manifesting as Wernicke-Korsakoff disease (en-
cephalopathy).
w e R N I C K e - K O R S A K O f f  S y N D R O M e
These two encephalopathies are caused by thiamine de-
ficiency in cases of malnutrition due to alcoholism and are 
attributed to nerve damage in the central and peripheral nerv-
ous systems. Wernicke’s encephalopathy produces confusion, 
ataxia, nystagmus, diplopia, and can progress to coma and 
death. Korsakof’s syndrome or psychosis relates to memory 
loss, confabulation and hallucinations. Stopping alcohol can 
prevent additional loss of brain function and nerve damage, 
while thiamine therapy may improve symptoms, but does not 
restore memory loss.
A l z h e I M e R ’ S  D I S e A S e
Lack of thiamine can cause dementia in Wernicke-Korsa-
koff syndrome. Therefore, researchers have speculated that 
thiamine might help Alzheimer’s disease.43
h e A R T  fA I l U R e
Thiamine deficiency was widespread in the developing 
world as a result of the exclusive use of polished rice as a 
staple diet in many Asian countries. With the realization that 
polished rice could lead to thiamine deficiency, a large number 
of certain populations may be at high risk for developing this 
deficiency, including heart failure. Thiamine may be related 
to heart failure in other ways, such as anorexia secondary to 
cardiac cachexia, use of alcohol, or end-stage renal disease; 
more commonly, many patients with HF receive diuretics, 
which help rid the body of excess fluid,44 but also increase 
thiamine excretion, which takes place in the distal nephron. 
Thus, use of high doses of diuretics in patients with HF can 
predispose them to thiamine deficiency. Therefore, the inter-
est in thiamine and thiamine deficiency, particularly in the HF 
population, has recently re-emerged. 
The aim of available therapies for HF has been firmly 
the prolongation of life expectancy. Although angiotensin 
converting enzyme inhibitors, β-blockers, aldosterone an-
tagonists, diuretics, implantable cardiac resynchronization 
therapy-pacemaker/defibrillator devices, have all improved 
morbidity and mortality in this population, mortality rates 
still remain high.
For several reasons, patients with HF may have micronutri-
ent deficiencies, one of which is thiamine deficiency.45 Thia-
mine supplementation may be an adjunct therapy in order to 
improve the prognosis and quality of life of patients with HF. 
The possible pathogenesis in the case of wet Beriberi 
(Table 1) is based on depletion of ATP from cardiac myocytes 
and the enhanced production of ATP releases in the plasma. 
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TABle 1. Features of thiamine deficiency
general features
Dry Beriberi /  
wernicke-Korsakoff Sydrome wet Beriberi
psychological symptoms: depression, emotional 
instability, mood liability, uncooperative 
behavior, fearfulness and agitation
Occulomotor abnormalities: 
ophthalmoplegia and optic 
neuropathy
High-output or low-output cardiac failure
Neurological symptoms: weakness, dizziness, 
insomnia, memory loss, peripheral neuropathy, 
pain sensitivity and sonophobia
Ataxia and gait abnormalities Systemic vasodilatation, pulmonary and 
peripheral edema, and fluid retention
Musculoskeletal symptoms: backache, myalgia, 
and muscular atrophy
Delirium, global confusion, 
psychosis, and coma
Metabolic acidosis, lactic acidosis
gastrointestinal symptoms: anorexia, nausea, 
vomiting and constipation
Peripheral neuropathy Palpitations, widened pulse pressure, hypotension, 
bradycardia at rest, and sinus arrhythmia
Seizures
Movement disorders:  
myoclonus and chorea
The ATP depletion causes weakening of the cardiac muscle 
function, finally leading to HF.46 Myocytes fail to produce 
ATP and so adenosine monophosphate is accumulated and 
converted to adenosine. The increased production of intracel-
lular adenosine provokes its build-up in the cells, eventually 
causing its release into the plasma. Adenosine in the plasma 
denotes as systemic vasodilation, flushing and headache. The 
derangement of reactions causes a blockade in the citric acid 
cycle thus preventing the conversion of pyruvate to acetyl-
CoA and ultimately ATP formation, causing cellular acidosis 
and increasing intracellular free fatty acid levels. The absence 
of ATP causes the body to upregulate glucolysis and use fat 
resources to accomplish its energy requirements. These fat 
resources proceed to not only provide energy but also produce 
ketones, which can be used for production of acetylo-CoA for 
extra hepatic tissues.
In chronic thiamine deficiency the body fat resources 
ultimately run out if other sources of acetyl-CoA such as 
ethanol are not being used. Therefore, stopping alcohol inges-
tion in patients with thiamine deficiency may actually result 
in rapid death of the patient.47 The pyruvate accumulation, 
from increased production caused by enhanced glycolysis and 
decreased utilization, because of its conversion to acetyl-CoA 
results in its alteration to lactate. The increased production 
of lactate ends up to lactic acidosis. This process severely 
disturbs the mechanisms of the normal cardiovascular system. 
The ventricular filling pressures are increased with increased 
oxygen consumption. The resistant vessel is damaged, which 
causes decreased peripheral vascular resistances leading to 
arteriovenous shunting of blood, increased cardiac output 
and venous congestion. Additionally, these patients can have 
signs and symptoms of increased catecholamine levels, low 
diastolic pressure and a widened pulse pressure resulting from 
the severe cardiovascular disturbances.
R I S K  fA C T O R S  f O R  T h I A M I N e  D e f I C I e N C y
As already alluded to, thiamine deficiency in patients 
with congestive HF is multifactorial.48 It may be present in 
these patients as a result of reasons irrelevant to HF, such 
inadequate dietary intake, advancing age, trauma, surgery, 
fever, malabsorption syndromes, severe infections, eating 
disorders, cancer, alcohol excess, inborn errors of metabolism, 
gastrointestinal surgery, persistent diarrhea, acquired immuno-
deficiency syndromes or drug therapy such as use of diuretics. 
Medications, such as phenyntoin, penicillins, cephalosporins, 
aminoglycodides, tetracycline derivatives, fluoroquinolones, 
sulphonamide derivatives, all may cause thiamine deficiency. 
Patients with HF experience early satiety and cachexia49 
both of which may be responsible for low dietary thiamine 
intake. In addition, the use of diuretics in combination with 
advanced age may be responsible for low levels of thiamine. 
50 The increase in venous pressure that is usual in chronic HF 
increases lymphatic production causing lymphatic obstruction, 
which impairs absorption from intestines and thus accelerates 
thiamine deficiency. In summary, the principal factors associ-
ated with thiamine deficiency in patients with HF are use of 
diuretics, malnutrition, preserved renal function, severe HF 
and advanced age (Table 2).
Thiamine has multiple effects on the cardiovascular sys-
tem. It has important hemodynamic effects on the circulatory 
system and direct positive effects on the heart. Low levels of 
thiamine contribute to the higher than normal basal metabolic 
rate in patients with HF.51 Thiamine deficiency is associated 
with depressed cardiac contractility, dysrhythmias and cardiac 
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hypertrophy. Several clinical trials have shown that thiamine 
supplementation increases the systolic, diastolic and central 
venous pressures, with an increase of left ventricular ejection 
fraction and a reduction of heart rate.52 Thiamine acts as a 
vasodilator and decreases the afterload, thus improving cardiac 
function. It has also suggested that thiamine may increase 
diuresis and natriuresis in patients with HF receiving diuretics, 
a beneficial effect for these individuals.
D O S A g e  f O R  T h I A M I N e  S U p p l e M e N T A T I O N
The recommended dosages of thiamine vary according to 
the case of proven deficiency. For example, the daily allowance 
is 1.1-1.2 mg/d orally but in patients at risk, thiamine should 
be given up to 200 mg three times a day (Table 3).
A rapid improvement of patient is generally noted after 
thiamine supplementation, as a result of sudden closure of 
arteriovenous shunts causing volume overload. As previously 
mentioned, thiamine deficiency can lead to de novo HF and 
adversely affect pre-existing cardiac dysfunction. Therefore, 
the prevalence of thiamine deficiency represents a dangerous 
clinical status in HF patients, which varies with the individual 
conditions of each population, their nutritional status, drug 
use and the presence of comorbid situation.
Thiamine deficiency is estimated to range from 21% to 
98% in patients with HF and its prevalence is higher in those 
with advanced age, taking diuretics, more severe failure, mul-
tiple diseases and varies in different studies (Table 4). The use 
of diuretics leads to thiamine deficiency because the excretion 
of thiamine in urine is directly proportional to urine flow. 
For that reason any increase of urine flow as occurs with use 
of diuretics may lead to an enhanced excretion of thiamine.
Furosemide has also been shown to reduce the uptake of 
thiamine by the cardiac myocytes.53 In addition, furosemide 
contributes to the development of thiamine deficiency because 
of its effects including anorexia, decreased intestinal thiamine 
TABle 2. Risk factors for thiamine deficiency
Diet Related Comorbid Conditions Others
Inadequate dietary intake, excess alcohol ingestion, 
malabsorption syndromes, eating disorders, and 
drugs such as diuretics, phenytoin, penicillins, 
cephalosporins, aminoglycosides, tetracycline 
derivatives, fluoroquinolones, sulfonamide derivatives, 
and trimethoprim
Heart failure, severe infections, 
trauma, surgery, cancer, acquired 
immunodeficiency syndrome, inborn 
errors of metabolism, gastrointestinal 
surgery, fever, and persistent diarrhea or 
vomiting
Advancing age, 
institutionalization, and 
frequent hospitalization
TABle 3. Dosage for thiamine supplementation
Recommended Daily Allowance 1.1-1.2 mg/d Orally
Risk of thiamine deficiency 100 mg 3 times daily until thiamine levels normalize
Proven thiamine deficiency 200 mg 3 times daily until thiamine levels normalize
Alcoholics without encephalopathy 50 mg/d orally
Patients on a refined grain diet 5-15 mg/d orally
Mild neuropathy 20-30 mg/d orally for 2 weeks
Severe neuropathy 20-30 mg/d orally for several weeks
Wet Beriberi 100 mg/d intravenous for several weeks
Prophylactic dose in HF 10-20 mg/d orally
TABle 4. Prevalence of thiamine deficiency in heart failure
Study prevalence
Wooley et al 21-98% in patients with heart failure
Sica 3-96% in patients with heart failure
Allard et al 13-93% in patients with heart failure
Lee et al 13-33% in patients with heart failure
Brady et al 21% in patients with heart failure
Levy et al 0% in younger patients with stable heart 
failure
Seligmann et al 91% in patients with heart failure and 
taking diuretics
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absorption and cellular hyponatremia or hypomagnesemia.54 
More specifically, patients with chronic HF who are taking 
furosemide >80 mg/d or bumetanide >2 mg/d for prolonged 
duration (>6 months) are at an especially increased risk for 
developing thiamine deficiency.55 Thus, patients with HF may 
be at risk for developing certain mirconutrient deficiencies 
including thiamine deficiency,56 and may benefit from thiamine 
supplementation, especially those at advanced stages. A recent 
meta-analysis of randomised double-blind, placebo-controlled 
trials has indicated that thiamine supplementation results in 
a significant improvement in net change of left ventricular 
ejection fraction (3.28%; 95% CI 0.64% - 5.98%) in patients 
with systolic HF.57
While more research is needed to fully elucidate the clinical 
impact of thiamine deficiency in chronic HF patients, recent 
evidence has indicated that supplementing with thiamine has 
the potential to improve left ventricular ejection fraction and 
in general to improve cardiac function, urine output, weight 
loss, signs and symptoms of HF. Therefore, this simple therapy 
should be tested in large scale randomized clinical trials to 
further determine the effect of thiamine in HF.
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